



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C07D 487/16, 471/16, A61K 31/4985, 31/551, A61P 25/00 // (C07D 487/16, 241:00, 239:00, 235:00) (C07D 471/16, 241:00, 235:00, 221:00) (C07D 487/16, 243:00, 239:00, 235:00) (C07D 471/16, 243:00, 235:00, 221:00)		A2	(11) International Publication Number: WO 00/27850
			(43) International Publication Date: 18 May 2000 (18.05.00)
(21) International Application Number: PCT/US99/26984		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 12 November 1999 (12.11.99)		Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(30) Priority Data: 09/190,958 12 November 1998 (12.11.98) US 09/400,744 21 September 1999 (21.09.99) US			
(71) Applicant (for all designated States except US): NEUROCRINE BIOSCIENCES, INC. [US/US]; 10555 Science Center Drive, San Diego, CA 92121 (US).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): HADDACH, Mustapha [MA/US]; 3545 Arnold Avenue, San Diego, CA 92104 (US). GUO, Zhiqiang [CN/US]; 11036 Caminito Alvarez, San Diego, CA 92126 (US). MCCARTHY, James, R. [US/US]; 4037 Oakleaf Drive, Zionsville, IN 46077 (US).			
(74) Agents: HERMANN, Karl, R. et al.; SEED and BERRY LLP, 6300 Columbia Center, 701 Fifth Avenue, Seattle, WA 98104-7092 (US).			
(54) Title: CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO			
<p style="text-align: center;">(I)</p>			
(57) Abstract			
<p>Compounds are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in warmblooded animals, including stroke. The compounds of this invention have structures (I): (a) wherein n, m, R, R_1, R_2, X and Ar are as defined herein, including stereoisomers and pharmaceutically acceptable salts thereof.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO

TECHNICAL FIELD

This invention relates generally to CRF receptor antagonists, and to methods of treating disorders by administration of such antagonists to a warm-blooded animal in need thereof.

BACKGROUND OF THE INVENTION

The first corticotropin-releasing factor (CRF) was isolated from ovine hypothalmi and identified as a 41-amino acid peptide (Vale et al., *Science* 213:1394-1397, 1981). Subsequently, sequences of human and rat CRF were isolated and determined to be identical, but different from ovine CRF in 7 of the 41 amino acid residues (Rivier et al., *Proc. Natl. Acad. Sci. USA* 80:4851, 1983; Shibahara et al., *EMBO J.* 2:775, 1983).

CRF has been found to produce profound alterations in endocrine, nervous and immune system function. CRF is believed to be the major physiological regulator of the basal and stress-release of adrenocorticotrophic hormone ("ACTH"), β -endorphin, and other pro-opiomelanocortin ("POMC")-derived peptides from the anterior pituitary (Vale et al., *Science* 213:1394-1397, 1981). Briefly, CRF is believed to initiate its biological effects by binding to a plasma membrane receptor which has been found to be distributed throughout the brain (DeSouza et al., *Science* 224:1449-1451, 1984), pituitary (DeSouza et al., *Methods Enzymol.* 124:560, 1986; Wynn et al., *Biochem. Biophys. Res. Comm.* 110:602-608, 1983), adrenals (Udelsman et al., *Nature* 319:147-150, 1986) and spleen (Webster, E.L., and E.B. DeSouza, *Endocrinology* 122:609-617, 1988). The CRF receptor is coupled to a GTP-binding protein (Perrin et al., *Endocrinology* 118:1171-1179, 1986) which mediates CRF-stimulated increase in intracellular production of cAMP (Bilezikian, L.M., and W.W. Vale, *Endocrinology* 113:657-662, 1983). The receptor for CRF has now been cloned from rat (Perrin et al., *Endo* 133(6):3058-3061, 1993), and human brain (Chen et al., *PNAS* 90(19):8967-8971, 1993; Vita et al., *FEBS* 335(1):1-5, 1993). This receptor is a 415 amino acid protein

comprising seven membrane spanning domains. A comparison of identity between rat and human sequences shows a high degree of homology (97%) at the amino acid level.

In addition to its role in stimulating the production of ACTH and POMC, CRF is also believed to coordinate many of the endocrine, autonomic, and behavioral responses to stress, and may be involved in the pathophysiology of affective disorders. Moreover, CRF is believed to be a key intermediary in communication between the immune, central nervous, endocrine and cardiovascular systems (Crofford et al., *J. Clin. Invest.* 90:2555-2564, 1992; Sapolsky et al., *Science* 238:522-524, 1987; Tilders et al., *Regul. Peptides* 5:77-84, 1982). Overall, CRF appears to be one of the pivotal central nervous system neurotransmitters and plays a crucial role in integrating the body's overall response to stress.

Administration of CRF directly to the brain elicits behavioral, physiological, and endocrine responses identical to those observed for an animal exposed to a stressful environment. For example, intracerebroventricular injection of CRF results in behavioral activation (Sutton et al., *Nature* 297:331, 1982), persistent activation of the electroencephalogram (Ehlers et al., *Brain Res.* 278:332, 1983), stimulation of the sympathoadrenomedullary pathway (Brown et al., *Endocrinology* 110:928, 1982), an increase of heart rate and blood pressure (Fisher et al., *Endocrinology* 110:2222, 1982), an increase in oxygen consumption (Brown et al., *Life Sciences* 30:207, 1982), alteration of gastrointestinal activity (Williams et al., *Am. J. Physiol.* 253:G582, 1987), suppression of food consumption (Levine et al., *Neuropharmacology* 22:337, 1983), modification of sexual behavior (Sirinathsinghji et al., *Nature* 305:232, 1983), and immune function compromise (Irwin et al., *Am. J. Physiol.* 255:R744, 1988). Furthermore, clinical data suggests that CRF may be hypersecreted in the brain in depression, anxiety-related disorders, and anorexia nervosa. (DeSouza, *Ann. Reports in Med. Chem.* 25:215-223, 1990). Accordingly, clinical data suggests that CRF receptor antagonists may represent novel antidepressant and/or anxiolytic drugs that may be useful in the treatment of the neuropsychiatric disorders manifesting hypersecretion of CRF.

The first CRF receptor antagonists were peptides (see, e.g., Rivier et al., U.S. Patent No. 4,605,642; Rivier et al., *Science* 224:889, 1984). While these peptides established that CRF receptor antagonists can attenuate the pharmacological responses to CRF, peptide CRF receptor antagonists suffer from the usual drawbacks of peptide therapeutics including lack of stability and limited oral activity. More recently, small molecule CRF receptor antagonists have been reported. For example, substituted 4-thio-5-oxo-3-pyrazoline derivatives (Abreu et al., U.S. Patent No. 5,063,245) and substituted 2-aminothiazole derivatives (Courtemanche et al., Australian Patent No. AU-A-41399/93) have been reported as CRF receptor antagonists. These particular derivatives were found to be effective in inhibiting the binding of CRF to its receptor in the 1-10 μ M range and 0.1-10 μ M range, respectively.


More recently, numerous small molecule CRR receptor antagonists have been proposed, including the compounds disclosed in the following patent documents: WO 94/13643, WO 94/13644, WO 94/13661, WO 94/13676, WO 94/13677, WO 95/10506, WO 95/33750, WO 96/35689, WO 97/00868, WO 97,35539, WO 97/35580, WO 97,35846, WO 97/44038, WO 98/03510, WO 98/05661, WO 98/08846, WO 98/08847, WO 98/11075, WO 98/15543, WO 98/21200 and WO 98/29413.

Due to the physiological significance of CRF, the development of biologically-active small molecules having significant CRF receptor binding activity and which are capable of antagonizing the CRF receptor remains a desirable goal. Such CRF receptor antagonists would be useful in the treatment of endocrine, psychiatric and neurologic conditions or illnesses, including stress-related disorders in general.

While significant strides have been made toward achieving CRF regulation through administration of CRF receptor antagonists, there remains a need in the art for effective small molecule CRF receptor antagonists. There is also a need for pharmaceutical compositions containing such CRF receptor antagonists, as well as methods relating to the use thereof to treat, for example, stress-related disorders. The present invention fulfills these needs, and provides other related advantages.

SUMMARY OF THE INVENTION

In brief, this invention is generally directed to CRF receptor antagonists, and more specifically to CRF receptor antagonists having the following general structure (I):



5

including stereoisomers and pharmaceutically acceptable salts thereof, wherein m , n , X , R , R_1 , R_2 and Ar are as defined below.


The CRF receptor antagonists of this invention have utility over a wide range of therapeutic applications, and may be used to treat a variety of disorders or 10 illnesses, including stress-related disorders. Such methods include administering an effective amount of a CRF receptor antagonist of this invention, preferably in the form of a pharmaceutical composition, to an animal in need thereof. Accordingly, in another embodiment, pharmaceutical compositions are disclosed containing one or more CRF receptor antagonists of this invention in combination with a pharmaceutically 15 acceptable carrier and/or diluent.

These and other aspects of the invention will be apparent upon reference to the following detailed description. To this end, various references are set forth herein which describe in more detail certain procedures, compounds and/or compositions, and are hereby incorporated by reference in their entirety.

20 DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed generally to compounds useful as corticotropin-releasing factor (CRF) receptor antagonists.

In a first embodiment, the CRF receptor antagonists of this invention have the following structure (I):



including stereoisomers and pharmaceutically acceptable salts thereof,

wherein:

n is 1 or 2;

5 *m* is 0, 1, 2 or 3;

X is N or CR';

R is an optional substituent which, at each occurrence, is independently C₁₋₆alkyl, C₃₋₆alkenyl C₁₋₆alkylidenyl or C₁₋₆alkylAr;

R' is hydrogen, halogen or C₁₋₆alkyl;

10 *R*₁ is -C(H)_{0,1}(R₃)(R₄);

*R*₂ is hydrogen or C₁₋₆alkyl;

*R*₃ is hydrogen, keto, C₁₋₆alkyl, mono- or di(C₃₋₆cycloalkyl)methyl, C₃₋₆cycloalkyl, C₃₋₆alkenyl, hydroxyC₁₋₆alkyl, C₁₋₆alkylcarbonyloxyC₁₋₆alkyl, or C₁₋₆alkyloxyC₁₋₆alkyl, and

15 *R*₄ is hydrogen, Ar¹, C₁₋₆alkylAr¹, OAr¹, C₁₋₈alkyl, C₁₋₆alkyloxy, C₃₋₆cycloalkyl, mono- or di(C₃₋₆cycloalkyl)methyl, C₃₋₆alkenyl, C₃₋₆alkynyl, C₁₋₆alkyloxyC₁₋₆alkyl, C₁₋₆alkoxyAr¹, hydroxyC₁₋₆alkyl, thienylC₁₋₆alkyl, furanylC₁₋₆alkyl, C₁₋₆alkylthioC₁₋₆alkyl, morpholinyl, mono- or di(C₁₋₆alkyl)aminoC₁₋₆alkyl, amino, (C₁₋₆alkyl)amino, di(C₁₋₆alkyl)amino,

20 (C₁₋₆alkylAr¹)amino, (C₁₋₆alkyl)(Ar¹)amino, C₁₋₆alkylcarbonylC₁₋₆alkyl, C₁₋₆alkylcarbonyloxyC₁₋₆alkyl, sulfonyl(C₁₋₈alkyl), C(=O)C₁₋₆alkyl, C₁₋₈alkyl substituted with phthalimide, Ar¹, OAr¹, NHAr¹, C(=O)Ar¹, C(=O)NHAr¹ or -C(=O)NH₂, or a radical of the formula -(C₁₋₆alkanediyl)-Y-(CO)_{0,1}-Ar¹ where Y is O, NH or a direct bond, or

25 *R*₃ and *R*₄ taken together with the carbon atom to which they are attached form a C₅₋₈cycloalkyl, a C₅₋₈cycloalkenyl, a C₃₋₁₂heterocycle, phenyl, naphthyl, or a

C₅₋₈cycloalkyl fused to Ar¹, each of which being optionally substituted with one or more substituents independently selected from C₁₋₆alkyl;

Ar is phenyl, naphthyl or an aromatic C₃₋₁₂heterocycle, each being optionally substituted with 1, 2 or 3 substituents independently selected from halo, 5 C₁₋₆alkyl, trifluoromethyl, O(trifluoromethyl), hydroxy, cyano, C₁₋₆alkyloxy, phenoxy, benzoxy, C₁₋₆alkylthio, nitro, amino, mono- or di(C₁₋₆alkyl)amino, (C₁₋₆alkyl)(C₁₋₆alkanoyl)amino, or piperidinyl, or wherein two substituents taken together are a C₁₋₆alkylidinyl or a C₁₋₆alkylidenyl having one, two or three carbon atoms replaced with a heteroatom individually selected from oxygen, nitrogen or and sulfur; and

10 Ar¹ is phenyl, naphthyl or an aromatic C₃₋₁₂heterocycle, each of which being optionally substituted with 1, 2 or 3 substituents independently selected from halo, C₁₋₆alkyl, C₁₋₆alkyloxy, di(C₁₋₆alkyl)amino, di(C₁₋₆alkyl)aminoC₁₋₆alkyl, trifluoromethyl sulfanyl(C₁₋₆alkyl), and C₁₋₆alkyl substituted with morpholinyl.

15 In the context of this invention, the preceding terms have the meanings set forth below.

“Keto” represents =O.

“C₁₋₆alkyl” or “C₁₋₈alkyl” represents a straight chain or branched alkyl having from 1 to 6 carbon atoms or 1 to 8 carbon atoms, respectively, 20 such as methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, n-pentyl, and the like.

“C₁₋₆alkyloxy” represents the group -O(C₁₋₆alkyl), such as methoxy, ethoxy, and the like.

“C₁₋₆alkylthio” represents the group -S(C₁₋₆alkyl), such as -SCH₃, -SCH₂CH₃, and the like.

“C₃₋₆cycloalkyl” represents a cyclic alkyl having from 3 to 6 carbon atoms, including cyclopropyl, cyclopentyl, cyclopentyl, and cyclohexyl.

“C₅₋₈cycloalkyl” represents a cyclic alkyl having from 5 to 8 carbon atoms, such as cyclopentyl, cyclohexyl, and the like.

“C₅₋₈cycloalkenyl” represents a cyclic alkyl having from 5 to 8 carbon atoms an at least one double bond.

5 “C₃₋₆alkenyl” represents an unsaturated straight chain or branched alkyl having from 3 to 6 carbon atoms, and having at least one double bond, such as propylenyl, 1-but enyl, 2-but enyl, 2-methylpropenyl, and the like.

10 “C₃₋₆alkynyl” represents an unsaturated straight chain or branched alkyl having from 3 to 6 carbon atoms, and having at least one triple bond, such as propynyl, 1-butynyl, 2-butynyl, 2-methylpropynyl, and the like.

“HydroxyC₁₋₆alkyl” represents a C₁₋₆alkyl substituted with at least one hydroxyl group, such as -CH₂OH, -CH(OH)CH₃, and the like.

15 “Mono- or di(C₃₋₆cycloalkyl)methyl” represents a methyl group substituted with one or two C₃₋₆cycloalkyl groups, such as cyclopropylmethyl, dicyclopropylmethyl, and the like.

“C₁₋₆alkylcarbonylC₁₋₆alkyl” represents a C₁₋₆alkyl substituted with a -COC₁₋₆alkyl group.

“C₁₋₆alkylcarbonyloxyC₁₋₆alkyl” represents a C₁₋₆alkyl substituted with a -COOC₁₋₆alkyl group.

20 “C₁₋₆alkyloxyC₁₋₆alkyl” represents a C₁₋₆alkyl substituted with a -OC₁₋₆alkyl group.

“C₁₋₆alkylthioC₁₋₆alkyl” represents a C₁₋₆alkyl substituted with a -SC₁₋₆alkyl group.

25 “Sulfanyl(C₁₋₆alkyl)” means -SO₂(C₁₋₆alkyl), such as -SO₂methyl and the like.

“Mono- or di(C₁₋₆alkyl)amino represents an amino substituted with one C₁₋₆alkyl or with two C₁₋₆alkyls, respectively.

“(C₁₋₆alkyl)(C₁₋₆alkanoyl)amino” represents an amino substituted with a C₁₋₆alkyl and a C₁₋₆alkanoyl (*i.e.*, C(=O)(C₁₋₆alkyl)).


“Mono- or di(C₁₋₆alkyl)aminoC₁₋₆alkyl” represents a C₁₋₆alkyl substituted with a mono- or di(C₁₋₆alkyl)amino.

“C₁₋₆alkylidenyl” represents a divalent C₁₋₆alkyl radical, such as methylene (-CH₂-), ethylene (-CH₂CH₂-), and the like.

5 “C₁₋₆alkylidenyl having one, two or three carbon atoms replaced with a heteroatom individually selected from oxygen, nitrogen or and sulfur” means a C₁₋₆alkylidenyl wherein one, two or three methylenyl groups (*i.e.*, “CH₂”) is replaced with O, N or S, such as -OCH₂O-, -OCH₂CH₂O-, and the like.





10 “C₃₋₁₂heterocycle” represents a ring made up of more than one kind of atom, and which contains 3 to 12 carbon atoms, such as pyridinyl, pyrimidinyl, furanyl, thienyl, imidazolyl, thiazolyl, pyrazolyl, pyridazinyl, pyrazinyl, triazinyl (such as 1,3,5), pyrrolyl, thiopenyl, oxazolyl, isoxazolyl, pyrrolinyl, pyrrolidinyl, piperidinyl, and the like, as well as heterocyclic rings fused to phenyl to form a bicyclic ring, 15 such as pyrrolidinophenyl and the like.

“Halo” means fluoro, chloro, bromo or iodo.





As used in the context of this invention, represents -CH₂CH₂-


20 or -CH=CH- optionally substituted with 1 or 2 R substituents (*i.e.*, when n = 1 and m = 0, 1 or 2), or -CH₂CH₂CH₂- optionally substituted with 1, 2 or 3 R substituents (*i.e.*, when n = 2 and m = 0, 1, 2 or 3). Accordingly, representative compounds of this invention include (but are not limited to) compounds having the following structures (I-1), (I-2), (I-3), (I-4), (I-5) and (I-6):




More specifically, and depending upon the choice of the X moiety, representative CRF receptor antagonists of this invention include compounds having the
 10 following structures (Ia) and (Ib), respectively:




In one preferred embodiment, the CRF receptor antagonists of this invention have structure (Ia). In another preferred embodiment, the CRF receptor antagonists of this invention have structure (Ib), wherein R' is hydrogen. Such compounds are represented by the following structures (I-1a), (I-1b), (I-4a) and (I-4b):




(I-1a)



(I-4a)




(I-1b)



(I-4b)


As noted above, R_1 is $-C(H)_{0,1}(R_3)(R_4)$ which represents $-CH(R_3)(R_4)$ and $-C(R_3)(R_4)$. Representative embodiments in this regard include the following R_1 moieties:

5



Similarly, when R_3 is keto, representative R_1 moieties include the following:


10




Representative R_1 moieties in this regard include $-C(=O)R_4$, $-C(=O)OR_4$, $-C(=O)NH_2$, $-C(=O)NH(C_{1-6}\text{alkyl})$ and $-C(=O)N(C_{1-6}\text{alkyl})(C_{1-6}\text{alkyl})$.

15

In the embodiment where the R_3 and R_4 groups of R_1 taken together form a C_{3-8} cycloalkyl, the resulting R_1 group has the structure:




Representative C₃₋₈cycloalkyls include cyclopropyl, cyclopentyl and cyclohexyl. Furthermore, when the C₃₋₈cycloalkyl is a C₅₋₇cycloalkyl, optionally substituted with 5 one or more C₁₋₆alkyl groups, a representative R₁ moiety has the following structure:



wherein R₅ and R₆ are the same or different and independently selected from a 10 C₁₋₆alkyl, such as methyl or ethyl.

Similarly, in the embodiment where the R₃ and R₄ groups of R₁ taken together form a C₅₋₈cycloalkyl fused to Ar, the resulting R₁ group has the structure:



15

including optionally substituted analogs thereof as defined above.

In more specific embodiments of this invention, representative Ar groups of this invention include 2,4,6-trimethylphenyl, 2-chloro-4-methylphenyl, 2-chloro-4-methoxyphenyl, 2-bromo-4-methylphenyl, 2-methyl-4-chlorophenyl, 2-methyl-4-bromophenyl, 2-bromo-4-isopropylphenyl, 2,4-dichlorophenyl, 2,6-dimethyl-4-bromophenyl, 4-chlorophenyl, 2,4-dimethoxyphenyl, 2,4-dimethylphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 2-methyl-4-methoxyphenyl, 3,4-dimethoxyphenyl, 3,5-dimethoxyphenyl, 4-trifluoromethylphenyl, 4-methoxyphenyl, 2,4,6-trifluorophenyl, 2-methyl-4-N(ethyl)₂phenyl, 2-bromo-4-(OCF₃)phenyl, 4-

dimethylamino-2-methyl-3-pyrdinyl, 4-dimethylamino-6-methyl-2-pyridinyl, 4-dimethylamino-3-pyridinyl, 4-N(CH₃)(COCH₃)-phenyl, 3,4-methylenedioxyphenyl and 3,4-ethylenedioxyphenyl.

Representative optional R groups of this invention include methyl, ethyl, 5 n-propyl, iso-propyl, iso-butyl, =CH₂ and =CHCH₃.


Representative R' groups are hydrogen, fluoro, chloro, bromo, methyl and ethyl, and preferably hydrogen.

Representative R₁ groups include methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, n-pentyl, iso-pentyl, neo-pentyl, -CH(ethyl)₂, -CH(n-propyl)₂, -CH(n-butyl)₂, -CH₂CH₂OCH₃, -CH(methyl)(CH₂OCH₃), -CH(ethyl)(CH₂OCH₃), -CH(n-propyl)(CH₂OCH₃), -CH(n-butyl)(CH₂OCH₃), -CH(tert-butyl)(CH₂OCH₃), -CH(CH₂OCH₃)₂, -CH(benzyl)(CH₂OCH₃), -CH(4-chlorobenzyl)(CH₂OCH₃), -CH(CH₂OCH₃)(CH₂CH₂SCH₃), -CH(ethyl)(CH₂Obenzyl), -CHC≡CH, -CH(methyl)(ethyl), -CH(methyl)(n-propyl), -CH(methyl)(n-butyl), -CH(methyl)(n-pentyl), -CH(methyl)(CH₂CH₂CH₂CH(CH₃)₂), -CH(ethyl)(n-propyl), -CH(ethyl)(n-butyl), -CH(ethyl)(n-pentyl), -CH(n-propyl)(n-butyl), -CH(n-propyl)(n-pentyl), cyclopropyl, cyclobutyl, cyclohexyl, 2-methylcyclohexyl, 3-methylcyclohexyl, 1,2,3,4-tetrahydronaphthyl (1 and 2), benzyl, 2-chlorobenzyl, -CH(methyl)(benzyl), -CH(ethyl)(benzyl), -CH(n-propyl)(benzyl), -CH(n-butyl)(benzyl), -CH₂(cyclopropyl), -CH₂(cyclobutyl), -CH₂CH(methyl)CH₂CH₃, -CH₂CH(ethyl)CH₂CH₃, -CH₂C(methyl)₃, -CH₂C≡CH, -CH₂C(=O)ethyl, -C(=O)cyclopropyl, -C(=O)NHbenzyl, -C(=O)methyl, -C(=O)benzyl, -C(=O)phenyl, -C(=O)ethyl, -C(=O)CH₂C(=O)Oethyl, -C(=O)CH(phenyl)ethyl, C(=O)pyridyl, -C(=O)(4-N,N-dimethylamino)phenyl, -C(=O)CH₂Omethyl, -C(=O)CH(ethyl)₂, -C(=O)n-butyl, -C(=O)CH₂CH₂(methyl)₂, -C(=O)n-propyl, -C(=O)CH₂CH₂phenyl, -CH₂pyridyl, -CH₂CH₂NHphenyl, -CH₂CH₂C(=O)Oethyl, -CH₂CH₂CH₂phenyl, -CH₂CH₂-N-phthalimide, -CH₂CH₂CH₂C(=O)Oethyl, -CH₂CH₂Oethyl, -CH₂CH(methyl)₂, -CH₂C(=O)Oethyl, -CH₂C(=O)pyrrohdinophenyl, -CH₂CH₂Ophenyl, -CH₂CH₂CH₂CH₂-N-phthalimide, -CH₂C(=O)Ot-butyl, -CH₂CH₂CH(methyl)₂, 30 -CH₂C(=O)NH₂, -CH₂-4-(SO₂CH₃)phenyl, -CH₂CH₂pyrolyl and benzyl.


Representative R₂ groups include methyl, ethyl and hydrogen, and preferably methyl.

The compounds of the present invention may be prepared by known organic synthesis techniques, including the methods described in more detail in the Examples, and may generally be utilized as the free base. Alternatively, the compounds of this invention may be used in the form of acid addition salts. Acid addition salts of the free base amino compounds of the present invention may be prepared by methods well known in the art, and may be formed from organic and inorganic acids. Suitable organic acids include maleic, fumaric, benzoic, ascorbic, succinic, methanesulfonic, acetic, oxalic, propionic, tartaric, salicylic, citric, gluconic, lactic, mandelic, cinnamic, aspartic, stearic, palmitic, glycolic, glutamic, and benzenesulfonic acids. Suitable inorganic acids include hydrochloric, hydrobromic, sulfuric, phosphoric, and nitric acids.


More specifically, the compounds of the structure (I) may be made according to the procedures set forth in Examples 1 and 2, as well as by the following general Reaction Scheme:

Reaction Scheme


5




10



15





The effectiveness of a compound as a CRF receptor antagonist may be determined by various assay methods. Suitable CRF antagonists of this invention are 5 capable of inhibiting the specific binding of CRF to its receptor and antagonizing activities associated with CRF. A compound of structure (I) may be assessed for activity as a CRF antagonist by one or more generally accepted assays for this purpose, including (but not limited to) the assays disclosed by DeSouza et al. (*J. Neuroscience* 7:88, 1987) and Battaglia et al. (*Synapse* 1:572, 1987). As mentioned above, suitable 10 CRF antagonists include compounds which demonstrate CRF receptor affinity. CRF receptor affinity may be determined by binding studies that measure the ability of a compound to inhibit the binding of a radiolabeled CRF (e.g., [¹²⁵I]tyrosine-CFR) to its receptor (e.g., receptors prepared from rat cerebral cortex membranes). The radioligand binding assay described by DeSouza et al. (*supra*, 1987) provides an assay for 15 determining a compound's affinity for the CRF receptor. Such activity is typically calculated from the IC₅₀ as the concentration of a compound necessary to displace 50% of the radiolabeled ligand from the receptor, and is reported as a "K_i" value calculated by the following equation:

$$20 \quad K_i = \frac{IC_{50}}{1 + L / K_D}$$

where L = radioligand and K_D = affinity of radioligand for receptor (Cheng and Prusoff, *Biochem. Pharmacol.* 22:3099, 1973).

In addition to inhibiting CRF receptor binding, a compound's CRF 25 receptor antagonist activity may be established by the ability of the compound to antagonize an activity associated with CRF. For example, CRF is known to stimulate

various biochemical processes, including adenylate cyclase activity. Therefore, compounds may be evaluated as CRF antagonists by their ability to antagonize CRF-stimulated adenylate cyclase activity by, for example, measuring cAMP levels. The CRF-stimulated adenylate cyclase activity assay described by Battaglia et al. (*supra*, 5 1987) provides an assay for determining a compound's ability to antagonize CRF activity. Accordingly, CRF receptor antagonist activity may be determined by assay techniques which generally include an initial binding assay (such as disclosed by DeSouza (*supra*, 1987)) followed by a cAMP screening protocol (such as disclosed by Battaglia (*supra*, 1987)).

10 With reference to CRF receptor binding affinities, CRF receptor antagonists of this invention have a K_i of less than 10 μM . In a preferred embodiment of this invention, a CRF receptor antagonist has a K_i of less than 1 μM , and more preferably less than 0.25 μM (*i.e.*, 250 nM). As set forth in greater detail below, representative compounds of this invention were assayed by the method of Example 4. 15 Preferred compounds having a K_i of less than 1 μM are compounds numbers (I-1) through (I-25) and (I-29) through (I-33). More preferred compounds having a K_i of less than 250 nM are compound numbers (I-1) through (I-14), (I-16) through (I-25) and (I-29) through (I-32).

20 The CRF receptor antagonists of the present invention demonstrate activity at the CRF receptor site, and may be used as therapeutic agents for the treatment of a wide range of disorders or illnesses including endocrine, psychiatric, and neurologic disorders or illnesses. More specifically, the CRF receptor antagonists of the present invention may be useful in treating physiological conditions or disorders arising from the hypersecretion of CRF. Because CRF is believed to be a pivotal 25 neurotransmitter that activates and coordinates the endocrine, behavioral and automatic responses to stress, the CRF receptor antagonists of the present invention can be used to treat neuropsychiatric disorders. Neuropsychiatric disorders which may be treatable by the CRF receptor antagonists of this invention include affective disorders such as depression; anxiety-related disorders such as generalized anxiety disorder, panic 30 disorder, obsessive-compulsive disorder, abnormal aggression, cardiovascular

abnormalities such as unstable angina and reactive hypertension; and feeding disorders such as anorexia nervosa, bulimia, and irritable bowel syndrome. CRF antagonists may also be useful in treating stress-induced immune suppression associated with various diseases states, as well as stroke. Other uses of the CRF antagonists of this invention

5 include treatment of inflammatory conditions (such as rheumatoid arthritis, uveitis, asthma, inflammatory bowel disease and G.I. motility), Cushing's disease, infantile spasms, epilepsy and other seizures in both infants and adults, and various substance abuse and withdrawal (including alcoholism).

In another embodiment of the invention, pharmaceutical compositions

10 containing one or more CRF receptor antagonists are disclosed. For the purposes of administration, the compounds of the present invention may be formulated as pharmaceutical compositions. Pharmaceutical compositions of the present invention comprise a CRF receptor antagonist of the present invention (*i.e.*, a compound of structure (I)) and a pharmaceutically acceptable carrier and/or diluent. The CRF

15 receptor antagonist is present in the composition in an amount which is effective to treat a particular disorder--that is, in an amount sufficient to achieve CRF receptor antagonist activity, and preferably with acceptable toxicity to the patient. Preferably, the pharmaceutical compositions of the present invention may include a CRF receptor antagonist in an amount from 0.1 mg to 250 mg per dosage depending upon the route of

20 administration, and more preferably from 1 mg to 60 mg. Appropriate concentrations and dosages can be readily determined by one skilled in the art.

Pharmaceutically acceptable carrier and/or diluents are familiar to those skilled in the art. For compositions formulated as liquid solutions, acceptable carriers and/or diluents include saline and sterile water, and may optionally include antioxidants, buffers, bacteriostats and other common additives. The compositions can also be formulated as pills, capsules, granules, or tablets which contain, in addition to a CRF receptor antagonist, diluents, dispersing and surface active agents, binders, and lubricants. One skilled in this art may further formulate the CRF receptor antagonist in an appropriate manner, and in accordance with accepted practices, such as those

disclosed in *Remington's Pharmaceutical Sciences*, Gennaro, Ed., Mack Publishing Co., Easton, PA 1990.

In another embodiment, the present invention provides a method for treating a variety of disorders or illnesses, including endocrine, psychiatric and 5 neurologic disorders or illnesses. Such methods include administering of a compound of the present invention to a warm-blooded animal in an amount sufficient to treat the disorder or illness. Such methods include systemic administration of a CRF receptor antagonist of this invention, preferably in the form of a pharmaceutical composition. As used herein, systemic administration includes oral and parenteral methods of 10 administration. For oral administration, suitable pharmaceutical compositions of CRF receptor antagonists include powders, granules, pills, tablets, and capsules as well as liquids, syrups, suspensions, and emulsions. These compositions may also include flavorants, preservatives, suspending, thickening and emulsifying agents, and other pharmaceutically acceptable additives. For parenteral administration, the compounds of 15 the present invention can be prepared in aqueous injection solutions which may contain, in addition to the CRF receptor antagonist, buffers, antioxidants, bacteriostats, and other additives commonly employed in such solutions.


As mentioned above, administration of a compound of the present invention can be used to treat a wide variety of disorders or illnesses. In particular, the 20 compounds of the present invention may be administered to a warm-blooded animal for the treatment of depression, anxiety disorder, panic disorder, obsessive-compulsive disorder, abnormal aggression, unstable angina, reactive hypertension, anorexia nervosa, bulimia, irritable bowel syndrome, stress-induced immune suppression, stroke, inflammation, Cushing's disease, infantile spasms, epilepsy, and substance abuse or 25 withdrawal.


The following examples are provided for purposes of illustration, not limitation.

EXAMPLES

The CRF receptor antagonists of this invention may be prepared by the methods disclosed in Examples 1-2. Example 3 discloses representative compounds of this invention. Example 4 presents a method for determining the receptor binding activity (K_i), and Example 5 discloses an assay for screening compounds of this invention for CRF-stimulated adenylate cyclase activity.

EXAMPLE 1

SYNTHESIS OF REPRESENTATIVE COMPOUNDS
10 OF STRUCTURE (IA)



Compound (4)

A solution of 4,6-dichloro-2-methyl-5-nitropyrimidine (3; *J. Chem. Soc.* 1954, 3836) (2.23 g, 11 mmol) in EtOH (30 mL) at -30°C was treated with 5 1-ethylpropylamine (870 mg, 10 mmol) in EtOH (8 mL) and the reaction mixture was stirred at -30 °C for 1 hour and then warmed to ambient temperature. Volatiles were evaporated and the residue was partitioned between water and EtOAc. The organic layer was dried (sodium sulfate), evaporated, purified by flash chromatography (silica) to give compound (4).

10 Compound (5)

A solution of compound (4) (2.07 g, 8 mmol) in acetonitrile (15 mL) was treated with 2,4,6-trimethylaniline (1.35 g, 10 mmol) at ambient temperature, then triethylamine (1.52 g, 15 mmol) was introduced. The reaction mixture was stirred at ambient temperature for 2 hours. Volatiles were evaporated and the residue was partitioned between brine and EtOAc. The organic layer was dried (sodium sulfate), evaporated, purified by flash chromatography (silica) to give compound (5).

Compound (6)

Compound (5) (2.14 g, 6 mmol) was dissolved in 1:1 dioxane/water (20 mL), and treated with concentrated aqueous ammonia hydroxide (5 mL). Sodium hydrosulfite (3.12 g, 18 mmol) was added in small batches over one hour and the solution was stirred at ambient temperature for 8 hours. The reaction mixture was partitioned between brine and EtOAc. The organic layer was dried (sodium sulfate), evaporated, purified by flash chromatography (silica) to give compound (6).

Compound (7)

A mixture of compound (6) (654 mg, 2 mmol) and triethylamine (500 mg) in dry THF (10 mL) was treated with triphosgene (217 mg, 0.73 mmol), and the reaction mixture was stirred at ambient temperature for 1 hour. Precipitates were 5 filtered and the filtrate was evaporated, and the residue was partitioned between brine and EtOAc. The organic layer was dried (sodium sulfate), evaporated, purified by flash chromatography (silica) to give compound (7).

Compound (8)

Compound (7) (353 mg, 1 mmol) in dry DMF (5 mL) was treated with 10 NaH (120 mg, 3 mmol, 60% in oil) at ambient temperature. Then 1,2-dibromoethane (654 mg, 3 mmol) was added to the reaction mixture and stirred for 10 hours. The reaction mixture was partitioned between water and EtOAc. The organic layer was dried (sodium sulfate), evaporated, purified by flash chromatography (silica) to give compound (8). LC-MS 380 (MH+).


15 Compound (9)


A solution of compound (8) (38 mg, 0.1 mmol) in toluene (2 ml) was treated with activated manganese dioxide catalyst (100 mg) at reflux for 16 hours. The catalyst was removed by filtration through a Celite pad and the filtrate was evaporated to dryness and purified by Prepatative TLC (silica gel) with ethyl acetate hexane (1:1) to 20 provide compound (9).

EXAMPLE 2

SYNTHESIS OF REPRESENTATIVE COMPOUNDS
OF STRUCTURE (Ib)

5 Compounds of structure (Ib) may be made by the same synthetic route as disclosed above in Example 1, but employing the corresponding pyridine to compound (1) rather than the pyrimidine. For example, representative compounds of this invention may be made by the following reaction scheme:





EXAMPLE 3


SYNTHESIS OF REPRESENTATIVE COMPOUNDS

5



Further representative compounds of this invention were made by general Reaction Scheme disclosed above and/or by the procedures of Examples 1 and 2, and are presented in the following Table.

10

Table
Representative Compounds



Cpd	R	X	R ₁	Ar
(I-1)	H	N	-CH(CH ₂ CH ₂ CH ₃) ₂	2,4,6-trimethylphenyl
(I-2)	H	CH	-CH(CH ₂ CH ₂ CH ₃) ₂	2-chloro-4-methylphenyl
(I-3)	H	CH	-CH(CH ₂ CH ₂ CH ₃) ₂	2-bromo-4-isopropylphenyl

Cpd	R	X	R ₁	Ar
(I-4)	H	CH	-CH(CH ₂ CH ₂ CH ₃) ₂	2,4-dichlorophenyl
(I-5)	H	CH	-CH(CH ₂ CH ₂ CH ₃) ₂	2,6-dimethyl-4-bromophenyl
(I-6)	H	CH	-CH(CH ₂ CH ₂ CH ₃) ₂	2-methyl-4-chlorophenyl
(I-7)	H	CH	-CH(CH ₂ CH ₂ CH ₃) ₂	2-bromo-4-methylphenyl
(I-8)	H	CH	-CH(CH ₂ CH ₂ CH ₃) ₂	4-chlorophenyl
(I-9)	H	CH	-CH(CH ₂ CH ₂ CH ₃) ₂	2,4-dimethoxyphenyl
(I-10)	H	CH	-CH(CH ₂ CH ₂ CH ₃) ₂	2-methoxyphenyl
(I-11)	H	CH	-CH(CH ₂ CH ₂ CH ₃) ₂	3,4-dimethoxyphenyl
(I-12)	H	CH	-CH(CH ₂ CH ₂ CH ₃) ₂	4-trifluoromethylphenyl
(I-13)	H	CH	-CH(CH ₂ CH ₂ CH ₃) ₂	4-methoxyphenyl
(I-14)	H	CH	-CH(CH ₂ CH ₂ CH ₃) ₂	2,4,6-trifluorophenyl
(I-15)	H	CH	-CH(CH ₂ CH ₂ CH ₃) ₂	2-methyl-4-(diethylamine)phenyl
(I-16)	H	CH	-CH(CH ₂ CH ₂ CH ₃) ₂	
(I-17)	H	CH	-CH(CH ₂ CH ₂ CH ₃) ₂	2-bromo-4-(OCF ₃)phenyl
(I-18)	H	CH	-CH(CH ₂ CH ₂ CH ₃) ₂	3-methoxyphenyl
(I-19)	H	CH	-CH(CH ₂ CH ₂ CH ₃) ₂	2,4-dimethylphenyl
(I-20)	H	CH	-CH(CH ₂ CH ₂ CH ₃) ₂	
(I-21)	H	CH	-CH(CH ₂ CH ₃)((CH ₂) ₃ CH ₃)	2-methyl-4-chlorophenyl
(I-22)	H	CH	-CH(CH ₂ CH ₃) ₂	2-methyl-4-chlorophenyl
(I-23)	H	CH	-CH(CH ₂ CH ₃)((CH ₂) ₂ CH ₃)	2-methyl-4-chlorophenyl
(I-24)	H	CH	-CH(CH ₂ CH ₃)((CH ₂) ₄ CH ₃)	2-methyl-4-chlorophenyl

Cpd	R	X	R ₁	Ar
(I-25)	H	CH	-CH((CH ₂) ₂ CH ₃)((CH ₂) ₃ CH ₃)	2-methyl-4-chlorophenyl
(I-26)	H	CH	-CH(CH ₂ CH ₂ CH ₃) ₂	3,5-dimethoxyphenyl
(I-27)	H	CH	-CH(CH ₂ CH ₂ CH ₃) ₂	3-(5-methylisoxazolyl)
(I-28)	H	CH	-CH(CH ₂ CH ₂ CH ₃) ₂	4-phenoxyphenyl
(I-29)	H	CH	-CH(CH ₂ CH ₂ CH ₃) ₂	4-methoxy-3-pyridinyl
(I-30)	H	CH	-CH(CH ₂ CH ₂ CH ₃) ₂	4-dimethylamine-3-pyridinyl
(I-31)	ethyl(S)	CH	-CH ₂ CH ₂ OCH ₃	4-methoxyphenyl
(I-32)	ethyl(S)	CH	-CH ₂ CH ₂ OH	4-methoxyphenyl
(I-33)	H	CH	-CH(CH ₂ CH ₂ CH ₃) ₂	4-(N-methyl-N-acetyl)phenyl
(I-34)	ethyl(S)	CH	-CH ₂ CH ₂ N(CH ₂ CH ₃) ₂	4-methoxyphenyl
(I-35)	H	CH	-CH(CH ₂ CH ₂ CH ₃) ₂	4-(COOMe)phenyl
(I-36)	H	CH	-CH(CH ₂ CH ₂ CH ₃) ₂	4-chloro-3-pyridinyl
(I-37)	H	CH	-CH(CH ₂ CH ₂ CH ₃) ₂	4-(COMe)phenyl
(I-38)	H	CH	-CH(CH ₂ CH ₂ CH ₃) ₂	4-(CH(OH)(CH ₃) ₂)phenyl
(I-39)	ethyl(S)	CH	C(O)CH ₃	4-methoxyphenyl
(I-40)	ethyl(S)	CH	C(O)CH ₂ Ph	4-methoxyphenyl
(I-41)	ethyl(S)	CH	C(O)Ph	4-methoxyphenyl
(I-42)	ethyl(S)	CH	C(O)CH ₂ CH ₃	4-methoxyphenyl
(I-43)	ethyl(S)	CH	C(O)CH ₂ CO ₂ CH ₂ CH ₃	4-methoxyphenyl
(I-44)	ethyl(S)	CH	C(O)Cyclopropyl	4-methoxyphenyl
(I-45)	ethyl(S)	CH	C(O)CH(Ph)CH ₂ CH ₃	4-methoxyphenyl
(I-46)	ethyl(S)	CH	C(O)4-Pyridyl	4-methoxyphenyl

Cpd	R	X	R ₁	Ar
(I-47)	ethyl(S)	CH	C(O)4-(N,N-Dimethylamino)phenyl	4-methoxyphenyl
(I-48)	ethyl(S)	CH	C(O)CH ₂ OCH ₃	4-methoxyphenyl
(I-49)	ethyl(S)	CH	C(O)3-Pyridyl	4-methoxyphenyl
(I-50)	ethyl(S)	CH	C(O)CH(CH ₂ CH ₃)CH ₂ CH ₃	4-methoxyphenyl
(I-51)	ethyl(S)	CH	C(O)CH ₂ CH ₂ CH ₂ CH ₃	4-methoxyphenyl
(I-52)	ethyl(S)	CH	C(O)CH ₂ CH(CH ₃) ₂	4-methoxyphenyl
(I-53)	ethyl(S)	CH	C(O)CH ₂ CH ₂ CH ₃	4-methoxyphenyl
(I-54)	ethyl(S)	CH	C(O)CH ₂ CH ₂ Ph	4-methoxyphenyl
(I-55)	ethyl(S)	CH	CH ₂ -3-Pyridyl	4-methoxyphenyl
(I-56)	ethyl(S)	CH	CH ₂ CH ₂ NHPh	4-methoxyphenyl
(I-57)	ethyl(S)	CH	CH ₂ CH ₂ CO ₂ CH ₂ CH ₃	4-methoxyphenyl
(I-58)	ethyl(S)	CH	CH ₂ CH ₂ CH ₂ Ph	4-methoxyphenyl
(I-59)	ethyl(S)	CH	CH ₂ CH ₂ -N-Phthalimide	4-methoxyphenyl
(I-60)	ethyl(S)	CH	CH ₂ CH ₂ CH ₂ CO ₂ CH ₂ CH ₃	4-methoxyphenyl
(I-61)	ethyl(S)	CH	CH ₂ CH ₂ OCH ₂ CH ₃	4-methoxyphenyl
(I-62)	ethyl(S)	CH	CH ₂ CH(CH ₃) ₂	4-methoxyphenyl
(I-63)	ethyl(S)	CH	CH ₂ CO ₂ CH ₂ CH ₃	4-methoxyphenyl
(I-64)	ethyl(S)	CH	CH ₂ C(O)(4-Pyrrolidinophenyl)	4-methoxyphenyl
(I-65)	ethyl(S)	CH	CH ₂ CH ₂ OPh	4-methoxyphenyl
(I-66)	ethyl(S)	CH	CH ₂ CH ₂ CH ₂ CH ₂ -N-Phthalimide	4-methoxyphenyl
(I-67)	ethyl(S)	CH	CH ₂ CO ₂ tBu	4-methoxyphenyl

Cpd	R	X	R ₁	Ar
(I-68)	ethyl(S)	CH	CH ₂ CH ₂ CH(CH ₃) ₂	4-methoxyphenyl
(I-69)	ethyl(S)	CH	CH ₂ C(O)NH ₂	4-methoxyphenyl
(I-70)	ethyl(S)	CH	CH ₂ -4-(SO ₂ CH ₃)Ph	4-methoxyphenyl
(I-71)	ethyl(S)	CH	CH ₂ CH ₂ -1-Pyrrole	4-methoxyphenyl
(I-72)	ethyl(S)	CH	CH ₂ Ph	4-methoxyphenyl

Cpd	Analytical data (MS/ ¹ H NMR)
(I-1)	0.92 (t, 6H), 1.25 -1.34 (m, 4H), 1.53-1.72 (m, 4H), 2.11 (s, 6H), 2.31 (s, 3H), 2.46 (s, 3H), 3.51 (t, 2H), 4.02 (t, 2H), 4.37-4.42 (m, 1H), 6.98 (s, 2H)
(I-2)	0.93 (t, 6H), 1.21-1.38 (m, 4H), 1.52 -1.60 (m, 2H), 1.64-1.75 (m, 2H), 2.34 (s, 3H), 2.49 (s, 3H), 3.41 (t, 2H), 3.72-3.79 (m, 1H), 3.92-4.12 (m, 2H), 6.25 (s, 1H), 7.05-7.78 (m, 3H)
(I-3)	0.93 (t, 6H), 1.26 (d, 6H), 1.27-1.35 (m, 4H), 1.52 -1.61 (m, 4H), 2.41 (s, 3H), 2.94 (hept, 1H), 3.40 (t, 2H), 3.73-3.82 (m, 1H), 3.89-4.11(m, 2H), 6.26 (s, 1H), 7.27-7.58 (m, 3H)
(I-4)	0.93 (t, 6H), 1.25-1.38 (m, 4H), 1.52 -1.62 (m, 4H), 2.40 (s, 3H), 3.40 (t, 2H), 3.72-3.78 (m, 1H), 3.90-4.11 (m, 2H), 6.26 (s, 1H), 7.26-7.57 (m, 3H)
(I-5)	LC/MS 471 (M+H)
(I-6)	0.93 (t, 6H), 1.25-1.39 (m, 4H), 1.51 -1.62 (m, 4H), 2.44 (s, 3H), 3.38 (t, 2H), 3.72-3.79 (m, 1H), 3.83 (s, 3H), 3.99 (t, 2H), 6.25 (s, 1H), 6.99 - 7.61 (m, 4H); MS (CI) <i>m/z</i> 395.10 (MH ⁺); HRMS (FAB) <i>m/z</i> 417.2277 (100; MNa ⁺ [C ₂₃ H ₃₀ N ₄ O ₂ Na] = 417.2266).
(I-7)	7.50 (d, 1H), 7.38 (d, 1H), 7.16 (dd, 1H), 6.42 (s, 1H), 4.28-4.39 (m, 1H), 4.09 (t, 2H), 3.81 (t, 2H), 1.92 (s, 6H), 1.88-2.01 (m, 2H), 1.64-1.75 (m, 2H), 1.21-1.35 (m, 4H), 0.91 (t, 6H).
(I-8)	7.72 (d, 2H), 7.38 (d, 2H), 6.20 (s, 1H), 3.92 (t, 2H), 3.63-3.72 (m, 1H), 3.32 (t, 2H), 2.38 (s, 3H), 1.40-1.57 (m, 4H), 1.17-1.32 (m, 4H), 0.86 (t, 6H).
(I-9)	LC/MS 425 (M+H)
(I-10)	LC/MS 395 (M+H)

Cpd	Analytical data (MS/ ¹ H NMR)
(I-11)	LC/MS 425 (M+H)
(I-12)	LC/MS 433 (M+H)
(I-13)	LC/MS 395 (M+H)
(I-14)	6.86 (d, 1H), 6.83 (d, 1H), 6.26 (s, 1H), 4.01 (t, 2H) < 3.69-3.80 (m, 1H), 3.40 (t, 2H), 2.41 (s, 3H), 1.47-1.67 (m, 4H), 1.25-1.39 (m, 4H), 0.83 (t, 6H).
(I-15)	7.10(d, 1H), 6.53-6.56(m, 2H), 6.22(s, 1H), 3.95-4.10(m, 2H), 3.70-3.82(m, 1H), 3.12-3.40(m, 6H), 2.40(s, 3H), 1.51-1.60(m, 4H), 1.23-1.38(m, 4H), 1.16(t, 6H), 0.895-0.960(m, 6H)
(I-16)	0.92 (t, 6H), 1.28-1.41 (m, 4H), 1.46 - 1.59 (m, 4H), 2.43 (s, 3H), 3.37 (t, 2H), 3.71-3.77 (m, 1H), 3.98 (t, 2H), 4.27 (s, 4H), 6.25 (s, 1H), 6.93 - 7.26 (m, 3H); MS (CI) <i>m/z</i> 423.20 (MH ⁺).
(I-17)	7.61(d, 1H), 7.49 (d, 1H), 7.31 (dd, 1H), 6.27 (s, 1H), 4.06-4.13 (dt, 1H), 3.89-3.97 (dt, 1H), 3.71-3.78 (m, 1H), 3.42 (t, 2H), 2.41 (s, 3H), 1.53-1.63 (m, 4H), 1.28-1.39 (m, 4H), 0.91-0.97 (m, 6H).
(I-18)	7.39-7.45(m, 1H), 6.10-7.076(m, 3H), 6.31(s, 1H), 4.04(t, 2H), 3.78-3.87(m, 4H), 3.52(t, 2H), 2.54(s, 3H), 1.59-1.67(m, 4H), 1.21-1.42(m, 4H), 0.95(t, 6H)
(I-19)	7.09-7.21(m, 3H), 6.23(s, 1H), 3.93-4.15(m, 2H), 3.71-3.77(m, 1H), 3.93(t, 2H), 2.39(s, 3H), 2.35(s, 3H), 1.49-1.65(m, 4H), 1.26-1.41(m, 4H), 0.90-0.96(m, 6H)
(I-20)	6.99 (dd, 1H), 7.00 (d, 1H), 6.72 (d, 1H), 6.07 (s, 1H), 5.82 (s, 2H), 3.81 (t, 2H), 3.51-3.61 (m, 1H), 3.20 (t, 2H), 2.26 (s, 3H), 1.33-1.50 (m, 4H), 1.07-1.21 (m, 4H), 0.75 (t, 6H).
(I-21)	7.35(s, 1H), 7.277-7.281(m, 2H), 6.27(s, 1H), 3.95-4.07 (m, 2H), 3.63(pentet, 1H), 3.41(t, 2H), 2.41(s, 3H), 2.25(s, 3H), 1.59-1.66(m, 4H), 1.19-1.36(m, 4H), 0.87-0.97(m, 6H)
(I-22)	7.35(s, 1H), 7.277-7.281(m, 2H), 6.27(s, 1H), 3.93-4.06 (m, 2H), 3.51-3.61(m, 1H), 3.41(t, 2H), 2.41(s, 3H), 2.25(s, 3H), 1.59-1.70(m, 4H), 0.95(t, 3H), 0.92(t, 3H)
(I-23)	7.35(s, 1H), 7.275-7.28(m 2H), 6.26(s, 1H), 3.91-4.1(m, 2H), 3.6-3.75(m, 1H), 3.41(t, 2H), 2.41(s, 3H), 2.24(s, 3H), 1.54-1.68(m, 4H), 1.30-1.42(m, 2H), 0.90-0.97(m, 6H)

Cpd	Analytical data (MS/ ¹ H NMR)
(I-24)	7.35(s, 1H), 7.278-7.282(m, 2H), 6.26(s, 1H), 3.92-4.10(m, 2H), 3.624(pentet, 1H), 3.41(t, 2H), 2.41(s, 3H), 2.25(s, 3H), 1.54-1.68(m, 4H), 1.20-1.38(m, 6H), 0.84-0.97(m, 6H)
(I-25)	7.35(s, 1H), 7.28(s, 2H), 62.4(s, 1H), 3.92-4.10(m, 2H), 3.72(pentet, 1H), 3.40(t, 2H), 2.40(s, 3H), 2.24(s, 3H), 1.56-1.62(m, 4H), 1.26-1.38(m, 6H), 0.86-0.97(m, 6H)
(I-26)	7.01 (d, 2H), 6.42 (t, 1H), 6.26 (s, 1H), 4.00 (t, 2H), 3.80 (s, 6H), 3.69-3.80 (m, 1H), 3.38 (t, 2H), 2.45 (s, 3H), 1.46-1.66 (m, 4H), 1.23-1.38 (m, 4H), 0.92 (t, 6H).
(I-27)	6.79 (d, 1H), 6.29 (s, 1H), 3.97 (t, 2H), 3.69-3.79 (m, 1H), 3.37 (t, 2H), 2.51 (s, 3H), 2.47 (d, 3H), 1.51-1.75 (m, 4H), 1.25-1.37 (m, 4H), 0.83-0.94 (m, 6H).
(I-28)	7.72 (d, 2H), 7.33-7.38 (m, 2H), 7.06-7.14 (m, 5H), 4.00 (t, 2H), 3.70-3.80 (m, 1H), 3.39 (t, 2H), 2.45 (s, 3H), 1.47-1.65 (m, 4H), 1.25-1.39 (m, 4H), 0.93 (t, 6H).
(I-29)	8.57 (d, 1H), 7.95 (dd, 1H)< 6.86 (d, 1H), 6.26 (s, 1H), 4.00 (t, 2H), 3.91 (s, 3H), 3.70-3.79 (m, 1H), 3.39 (t, 2H), 2.43 (s, 3H), 1.51-1.67 (m, 4H), 1.25-1.38 (m, 4H), 0.92 (t, 6H).
(I-30)	0.92 (t, 6H), 1.25-1.38 (m, 4H), 1.51 -1.62 (m, 4H), 2.42 (s, 3H), 3.12 (s, 6H), 3.38 (t, 2H), 3.71 -3.77 (m, 1H), 3.99 (t, 2H), 6.24 (s, 1H), 6.63 - 8.47 (m, 3H); MS (CI) <i>m/z</i> 409.20 (MH ⁺).
(I-31)	7.66(d, 2H), 7.01(d, 2H), 6.2(s, 1H), 4.18(dd, 1H), 3.84(s, 3H), 3.54-3.72(m, 5H), 3.38-3.44(m, 1H), 3.37(s, 3H), 2.45(s, 3H), 1.31-1.73(m, 2H), 1.00(t, 3H)
(I-32)	7.62(d, 2H), 7.01(d, 2H), 6.23(s, 1H), 4.23(dd, 1H), 3.84(s, 3H), 3.60-3.81(m, 5H), 3.31-3.40(m, 1H), 2.44(s, 3H), 1.5-1.72(m, 2H), 1.01(t, 3H)
(I-33)	7.94(d, 2H), 7.30(d, 2H), 6.29(s, 1H), 4.01(t, 2H), 3.76(s, 1H), 3.41(t, 2H), 3.28(s, 3H), 2.48(s, 3H), 1.96(t, 3H), 1.49-1.68(m, 4H), 1.25-1.37(m, 4H), 0.94(t, 6H)
(I-34)	7.64(d, 2H), 7.01(d, 2H), 6.2(s, 1H), 4.18(dd, 1H), 3.84(s, 3H), 3.56-3.74(m, 3H), 3.22-3.32(m, 1H), 2.55-2.65(m, 6H), 2.45(s, 3H), 1.52-1.73(m, 2H), 0.98-1.07(m, 9H)

Cpd	Analytical data (MS/ ¹ H NMR)
(I-35)	δ 8.16 (d, 2H), 8.05 (d, 2H), 6.28 (s, 1H), 4.00t, 2H), 3.93 (s, 3H), 3.71-3.81 (m, 1H), 3.39 (t, 2H), 2.47 (s, 3H), 1.52-1.65 (m, 4H), 1.28-1.39 (m, 4H), 0.92 (t, 6H).
(I-36)	δ 8.60 (d, 1H), 7.82 (dd, 1H), 7.74 (d, 1H), 6.29 (s, 1H), 3.99 (t, 2H), 3.73-3.78 (m, 1H), 3.87 (t, 2H), 2.48 (s, 3H), 1.51-1.62 (m, 4H), 1.25-1.38 (m, 4H), 0.92 (t, 6H).
(I-37)	δ 8.08 (s, 4H), 6.29 (s, 1H), 4.00 (t, 2H), 3.71-3.81 (m, 1H), 3.97 (t, 2H), 2.62 (s, 3H), 2.47 (s, 3H), 1.52-1.62 (m, 4H), 1.22-1.39 (m, 4H), 0.93 (t, 6H).
(I-38)	δ 7.72 (d, 2H), 7.60 (d, 2H), 6.27 (s, 1H), 4.00 (t, 2H), 3.68-3.82 (m, 1H), 3.48 (s, 6H), 3.39 (t, 3H), 2.45 (s, 3H), 1.54-1.63 (m, 4H), 1.24-1.38 (m, 4H), 1.08 (t, 3H), 0.93 (t, 3H).

EXAMPLE 4

CRF RECEPTOR BINDING ACTIVITY

The compounds of this invention may be evaluated for binding activity to the CRF receptor by a standard radioligand binding assay as generally described by 5 DeSouza et al. (*J. Neurosci.* 7:88-100, 1987). By utilizing various radiolabeled CRF ligands, the assay may be used to evaluate the binding activity of the compounds of the present invention with any CRF receptor subtype. Briefly, the binding assay involves the displacement of a radiolabeled CRF ligand from the CRF receptor.

More specifically, the binding assay is performed in 1.5 ml Eppendorf 10 tubes using approximately 1×10^6 cells per tube stably transfected with human CRF receptors. Each tube receives about 0.1 ml of assay buffer (e.g., Dulbecco's phosphate buffered saline, 10 mM magnesium chloride, 20 μ M bacitracin) with or without unlabeled sauvagine, urotensin I or CRF (final concentration, 1 μ M) to determine nonspecific binding, 0.1 ml of [¹²⁵I] tyrosine - ovine CRF (final concentration ~200 pM 15 or approximately the K_D as determined by Scatchard analysis) and 0.1 ml of a membrane suspension of cells containing the CRF receptor. The mixture is incubated for 2 hours at 22°C followed by the separation of the bound and free radioligand by centrifugation. Following two washes of the pellets, the tubes are cut just above the

pellet and monitored in a gamma counter for radioactivity at approximately 80% efficiency. All radioligand binding data may be analyzed using the non-linear least-square curve-fitting program LIGAND of Munson and Rodbard (*Anal. Biochem.* 107:220, 1990).

5

EXAMPLE 5

CRF-STIMULATED ADENYLYLATE CYCLASE ACTIVITY

The compounds of the present invention may also be evaluated by various functional testing. For example, the compounds of the present invention may be screened for CRF-stimulated adenylate cyclase activity. An assay for the determination 10 of CRF-stimulated adenylate cyclase activity may be performed as generally described by Battaglia et al. (*Synapse* 1:572, 1987), with modifications to adapt the assay to whole cell preparations.


More specifically, the standard assay mixture may contain the following in a final volume of 0.5 ml: 2 mM L-glutamine, 20 mM HEPES, and 1 mM IBMX in 15 DMEM buffer. In stimulation studies, whole cells with the transfected CRF receptors are plated in 24-well plates and incubated for 1 h at 37°C with various concentrations of CRF-related and unrelated peptides in order to establish the pharmacological rank-order profile of the particular receptor subtype. Following the incubation, the media is aspirated, the wells rinsed once gently with fresh media, and the media aspirated. To 20 determine the amount of intracellular cAMP, 300 µl of a solution of 95% ethanol and 20 mM aqueous hydrochloric acid is added to each well and the resulting suspensions are incubated at -20°C for 16 to 18 hours. The solution is removed into 1.5 ml Eppendorf tubes and the wells washed with an additional 200 µl of ethanol/aqueous hydrochloric acid and pooled with the first fraction. The samples are lyophilized and 25 then resuspended with 500 µl sodium acetate buffer. The measurement of cAMP in the samples is performed using a single antibody kit from Biomedical Technologies Inc. (Stoughton, MA). For the functional assessment of the compounds, a single concentration of CRF or related peptides causing 80% stimulation of cAMP production

is incubated along with various concentrations of competing compounds (10^{-12} to 10^{-6} M).

It will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications 5 may be made without departing from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

CLAIMS

1. A compound having the following structure:



and stereoisomers and pharmaceutically acceptable salts thereof,

wherein:

n is 1 or 2;

m is 0, 1, 2 or 3;

X is N or CR';

R is an optional substituent which, at each occurrence, is independently C₁₋₆alkyl, C₃₋₆alkenyl C₁₋₆alkylidenyl or C₁₋₆alkylAr;

R₁ is -C(H)_{0,1}(R₃)(R₄);

R₂ is hydrogen or C₁₋₆alkyl;

R₃ is hydrogen, keto, C₁₋₆alkyl, mono- or di(C₃₋₆cycloalkyl)methyl, C₃₋₆cycloalkyl, C₃₋₆alkenyl, hydroxyC₁₋₆alkyl, C₁₋₆alkylcarbonyloxyC₁₋₆alkyl, or C₁₋₆alkyloxyC₁₋₆alkyl, and

R₄ is hydrogen, Ar¹, C₁₋₆alkylAr¹, OAr¹, C₁₋₈alkyl, C₁₋₆alkyloxy, C₃₋₆cycloalkyl, mono- or di(C₃₋₆cycloalkyl)methyl, C₃₋₆alkenyl, C₃₋₆alkynyl, C₁₋₆alkyloxyC₁₋₆alkyl, C₁₋₆alkoxyAr¹, hydroxyC₁₋₆alkyl, thienylC₁₋₆alkyl, furanylC₁₋₆alkyl, C₁₋₆alkylthioC₁₋₆alkyl, morpholinyl, mono- or di(C₁₋₆alkyl)aminoC₁₋₆alkyl, amino, (C₁₋₆alkyl)amino, di(C₁₋₆alkyl)amino, (C₁₋₆alkylAr¹)amino, (C₁₋₆alkyl)(Ar¹)amino, C₁₋₆alkylcarbonylC₁₋₆alkyl, C₁₋₆alkylcarbonyloxyC₁₋₆alkyl, sulfonyl(C₁₋₈alkyl), C(=O)C₁₋₆alkyl, C₁₋₈alkyl substituted with phthalimide, Ar¹, OAr¹, NHAr¹, C(=O)Ar¹, C(=O)NAr¹ or -C(=O)NH₂, or a radical of the formula -(C₁₋₆alkanediyl)-Y-(CO)_{0,1}-Ar¹ where Y is O, NH or a direct bond, or

WO 00/27850


R_3 and R_4 taken together with the carbon atom to which they are attached form a C_{5-8} cycloalkyl, a C_{5-8} cycloalkenyl, a C_{3-12} heterocycle, phenyl, naphthyl, or a C_{5-8} cycloalkyl fused to Ar^1 , each of which being optionally substituted with one or more substituents independently selected from C_{1-6} alkyl;

Ar is phenyl, naphthyl or an aromatic C_{3-12} heterocycle, each being optionally substituted with 1, 2 or 3 substituents independently selected from halo, C_{1-6} alkyl, trifluoromethyl, O (trifluoromethyl), hydroxy, cyano, C_{1-6} alkyloxy, phenoxy, benzoxy, C_{1-6} alkylthio, nitro, amino, mono- or di(C_{1-6} alkyl)amino, $(C_{1-6}$ alkyl)(C_{1-6} alkanoyl)amino, or C_{1-6} alkylidinyl, or wherein two substituents taken together are a C_{1-6} alkylidinyl or a C_{1-6} alkylidenyl having one, two or three carbon atoms replaced with a heteroatom individually selected from oxygen, nitrogen or and sulfur; and


Ar^1 is phenyl, naphthyl or an aromatic C_{3-12} heterocycle, each of which being optionally substituted with 1, 2 or 3 substituents independently selected from halo, C_{1-6} alkyl, C_{1-6} alkyloxy, di(C_{1-6} alkyl)amino, di(C_{1-6} alkyl)amino C_{1-6} alkyl, trifluoromethyl sulfonyl (C_{1-6} alkyl) and C_{1-6} alkyl substituted with morpholinyl.

2. The compound of claim 1 wherein n is 1.


3. The compound of claim 2 having the structure




4. The compound of claim 2 having the structure




5. The compound of claim 1 wherein *n* is 2.
6. The compound of claim 5 having the structure




7. The compound of claim 1 wherein *m* is 0.
8. The compound of claim 7 having the structure:




9. The compound of claim 7 having the structure:
10. The compound of claim 1 wherein *m* is 1.




11. The compound of claim 10 having the structure:



12. The compound of claim 10 having the structure:



13. The compound of claim 10 having the structure:



14. The compound of claim 1 wherein X is CR' and R' is hydrogen.

15. The compound of claim 1 wherein X is N.

16. The compound of claim 1 wherein R is C₁₋₆alkyl.

17. The compound of claim 1 wherein R is methyl or ethyl.

18. The compound of claim 1 wherein R is ethyl.

19. The compound of claim 1 wherein Ar is 2,4,6-trimethylphenyl, 2-chloro-4-methylphenyl, 2-chloro-4-methoxyphenyl, 2-bromo-4-methylphenyl, 2-methyl-4-chlorophenyl, 2-methyl-4-bromophenyl, 2-bromo-4-isopropylphenyl, 2,4-dichlorophenyl, 2,6-dimethyl-4-bromophenyl, 4-chlorophenyl, 2,4-dimethoxyphenyl, 2,4-dimethylphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-methyl-4-methoxyphenyl, 3,4-dimethoxyphenyl, 3,5-dimethoxyphenyl, 4-trifluoromethylphenyl, 2,4,6-trifluorophenyl, 2-methyl-4-N(ethyl)₂phenyl, 2-bromo-4-(OCF₃)phenyl, 4-dimethylamino-2-methylpyridin-3-yl, 4-dimethylamino-6-methylpyridin-3-yl, 4-dimethylamino-pyridin-3-yl, 4-N(CH₃)(Ac)phenyl, 5-methylisoxazol-3-yl, 3,4-methylenedioxyphenyl or 3,4-ethylenedioxyphenyl.

20. The compound of claim 1 wherein Ar is 2,4,6-trimethylphenyl, 2-methyl-4-chlorophenyl, 2-chloro-4-methylphenyl, 2,4-dichlorophenyl, 2,6-dimethyl-4-bromophenyl, 2-bromo-4-methylphenyl, 4-methoxyphenyl or 4-chlorophenyl.

21. The method of claim 1 wherein R₁ is methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, tert-butyl, n-pentyl, iso-pentyl, neo-pentyl, -CH(ethyl)₂, -CH(n-propyl)₂, -CH(n-butyl)₂, -CH₂CH₂OCH₃, -CH(methyl)(CH₂OCH₃), -CH(ethyl)(CH₂OCH₃), -CH(n-propyl)(CH₂OCH₃), -CH(n-butyl)(CH₂OCH₃), -CH(tert-butyl)(CH₂OCH₃), -CH(CH₂OCH₃)₂, -CH(benzyl)(CH₂OCH₃), -CH(4-chlorobenzyl)(CH₂OCH₃), -CH(CH₂OCH₃)(CH₂CH₂SCH₃), -CH(ethyl)(CH₂Obenzyl), -CHC≡CH, -CH(methyl)(ethyl), -CH(methyl)(n-propyl), -CH(methyl)(n-butyl), -CH(methyl)(n-pentyl), -CH(methyl)(CH₂CH₂CH₂CH(CH₃)₂), -CH(ethyl)(n-propyl), -CH(ethyl)(n-butyl), -CH(ethyl)(n-pentyl), -CH(n-propyl)(n-butyl), -CH(n-propyl)(n-pentyl), cyclopropyl, cyclobutyl, cyclohexyl, 2-methylcyclohexyl, 3-methylcyclohexyl, 1,2,3,4-tetrahydronaphthyl (1 and 2), benzyl, 2-chlorobenzyl, -CH(methyl)(benzyl), -CH(ethyl)(benzyl), -CH(n-propyl)(benzyl), -CH(n-butyl)(benzyl), -CH₂(cyclopropyl), -CH₂(cyclobutyl), -CH₂CH(methyl)CH₂CH₃, -CH₂CH(ethyl)CH₂CH₃, -CH₂C(methyl)₃, -CH₂C≡CH, -CH₂C(=O)ethyl, -C(=O)cyclopropyl, -C(=O)NHbenzyl, -C(=O)methyl, -C(=O)benzyl, -C(=O)phenyl, -C(=O)ethyl, -C(=O)CH₂C(=O)Oethyl, -C(=O)CH(phenyl)ethyl, C(=O)pyridyl, -C(=O)(4-N,N-dimethylamino)phenyl, -C(=O)CH₂Omethyl,

-C(=O)CH(ethyl)₂, -C(=O)n-butyl, -C(=O)CH₂CH₂(methyl)₂, -C(=O)n-propyl,
-C(=O)CH₂CH₂phenyl, -CH₂pyridyl, -CH₂CH₂NHphenyl, -CH₂CH₂C(=O)Oethyl,
-CH₂CH₂CH₂phenyl, -CH₂CH₂-N-phthalimide, -CH₂CH₂CH₂C(=O)Oethyl, -CH₂CH₂Oethyl,
-CH₂CH(methyl)₂, -CH₂C(=O)Oethyl, -CH₂C(=O)pyrroldinophenyl, -CH₂CH₂Ophenyl,
-CH₂CH₂CH₂CH₂-N-phthalimide, -CH₂C(=O)O-t-butyl, -CH₂CH₂CH(methyl)₂,
-CH₂C(=O)NH₂, -CH₂-4-(SO₂CH₃)phenyl, -CH₂CH₂pyrolyl and benzyl.

22. The compound of claim 1 wherein R₁ is -CH(ethyl)₂, -CH(n-propyl)₂,
-CH(ethyl)(n-butyl) or -CH(ethyl)(n-pentyl).

23. A pharmaceutical composition comprising a compound of claim 1 and
a pharmaceutically acceptable carrier.

24. A method for treating a disorder manifesting hypersecretion of CRF in
a warm-blooded animal in need thereof, comprising administering to the animal an effective
amount of the pharmaceutical composition of claim 23.

25. The method of claim 24 wherein the disorder is stroke.

26. The method of claim 24 wherein the disorder is depression, anxiety
disorder, panic disorder, obsessive-compulsive disorder, abnormal aggression, unstable
angina, reactive hypertension, anorexia nervosa, bulimia, irritable bowel syndrome, stress-
induced immune suppression, inflammation, Cushing's disease, substance abuse or
withdrawal, infantile spasms, or epilepsy.